LA
BIIB icon

Lindenwold Advisors’s Biogen BIIB Stock Holding History

Lindenwold Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,605
Closed -$893K – 112
2024
Q3 		$893K Buy
4,605
+55
+1% +$11.5K 0.45% 56
2024
Q2 		$1.05M Buy
4,550
+30
+0.7% +$6.52K 0.56% 51
2024
Q1 		$975K Buy
4,520
+1,640
+57% +$384K 0.52% 52
2023
Q4 		$745K Sell
2,880
-1,804
-39% -$443K 0.42% 55
2023
Q3 		$1.2M Buy
4,684
+29
+0.6% +$7.76K 0.75% 44
2023
Q2 		$1.33M Sell
4,655
-845
-15% -$252K 0.81% 41
2023
Q1 		$1.53M Buy
5,500
+70
+1% +$19.4K 0.95% 38
2022
Q4 		$1.5M Buy
5,430
+54
+1% +$15.3K 1.01% 37
2022
Q3 		$1.44M Buy
5,376
+38
+0.7% +$8.07K 1.06% 32
2022
Q2 		$1.09M Buy
5,338
+31
+0.6% +$6.34K 0.77% 48
2022
Q1 		$1.12M Buy
5,307
+209
+4% +$45.4K 0.69% 48
2021
Q4 		$1.22M Buy
+5,098
New +$1.31M 0.71% 47

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lindenwold Advisors's BIIB Position: Q4 2024 in Review

Lindenwold Advisors sold out of Biogen (BIIB) in Q4 2024, closing a stake of 4,605 shares — an estimated $893K sold.

Lindenwold Advisors first reported a position in BIIB in Q4 2021 and held it in 12 quarters. The position peaked at $1.53M in Q1 2023. 875 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

  • Lindenwold Advisors reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
  • Lindenwold Advisors sold 4,605 Biogen shares in Q4 2024, an estimated $893K.
  • Lindenwold Advisors first reported a position in Biogen in Q4 2021 and held it in 12 quarters.
  • Lindenwold Advisors's Biogen position peaked at $1.53M in Q1 2023.
  • 875 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on Lindenwold Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.